2.45Open2.45Pre Close0 Volume17 Open Interest8.00Strike Price0.00Turnover0.00%IV-159.95%PremiumAug 16, 2024Expiry Date5.87Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.36Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Amylyx Pharmaceuticals Stock Discussion
Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for Amx0035 for the Treatment of Wolfram Syndrome
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has recently announced the acquisition of avexitide from Eiger BioPharmaceuticals, Inc. Avexitide has already garnered considerable attention for its potential therapeutic benefits and has received designations from the U.S. Food and Drug Administration (FDA). This article delve...
Dow Jones· 11 mins ago! Is to enter Phase 3 Trial in Q1 2025!
No comment yet